The Stanford Cancer Institute Breakthroughs in Cancer seminar series is one of the highest-profile seminar series for translational and clinical scientists in oncology. The series brings national leaders in cancer research to Stanford’s campus and highlights innovations across the spectrum of basic, translational, clinical, and population science. 

Join us Tuesday, November 11, 4-5 p.m., at Munzer Auditorium, Beckman Center or Zoom for a presentation by Benjamin L. Ebert, MD PhD, professor of medicine at Harvard Medical School, president and CEO of Dana-Farber Cancer Institute.

Dr. Ebert's laboratory focuses on the molecular basis and treatment of hematologic malignancies and their non-malignant precursor conditions, with a particular focus on myelodysplastic syndromes (MDS) and clonal hematopoiesis. The Ebert laboratory demonstrated that lenalidomide, a derivative of thalidomide, binds the CRL4-CRBN E3 ubiquitin ligase and induces degradation of specific substrates. Subsequent research has examined novel mechanisms of drug-induced protein degradation that expand the spectrum of protein substrates that can be targeted pharmacologically. His presentation will discuss how clonal hematopoiesis increases the risk of blood cancers, inflammatory diseases, and overall mortality.

The event is open to Stanford Cancer Institute members, postdocs, fellows, and students, as well as Stanford University and Stanford Medicine faculty, trainees, and staff interested in basic, translational, clinical, and population-based cancer research.

Registration is encouraged.